Renzapride Accelerates Colonic Transit in IBS-C Patients

Published Online: Wednesday, December 1, 2004

The pathophysiology of irritable bowel syndrome (IBS) is thought to be multifactorial, and physical and psychosocial factors may contribute to overall symptom presentation. Therapies that target these contributing factors have been developed.

Renzapride is a serotonin type 4 receptor agonist/type 3 receptor antagonist. The effect of this agent on colonic transit (CT) in patients with IBS with constipation (IBS-C; n = 48, of whom 46 were women) was examined. The findings of this study were published in the October 2004 issue of Clinical Gastroenterology and Hepatology.

Results demonstrated a linear dose response to renzapride for CT and ascending colon emptying, but not for gastric emptying or small bowel transit. The median ascending colon half-time transit was 5.0 hours in patients treated with 4 mg renzapride (n = 12), compared with 17.5 hours in those in the placebo group (n = 12). Improved bowel function scores (ie, stool form, ease of passage) were significantly (P < .05) associated with accelerated CT. The authors concluded that renzapride causes clinically significant CT acceleration, which is associated with bowel function improvement in women with IBS-C.

Latest Articles
Pharmacies are rated as some of the best places to receive top-notch customer service in America.
Often caused by acid reflux, eosinophilic esophagitis is an emerging inflammatory disease that is generally unresponsive to proton pump inhibitor therapy.
Carlos Aquino, founder and president of PharmaDiversion LLC, discusses timing of inspections from the Drug Enforcement Administration.
The FDA has again rejected AMAG Pharmaceuticals’ application for a single-dose version of hydroxyprogesterone caproate injection (Makena) to reduce the risk of preterm birth for at-risk women.
Latest Issues